Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Capital Expenditures (2016 - 2025)

Northwest Biotherapeutics' Capital Expenditures history spans 15 years, with the latest figure at $905000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $905000.0 for Q4 2025, up 1060.26% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (up 48.32% YoY), and the annual figure for FY2025 was $1.5 million, up 48.32%.
  • Capital Expenditures for Q4 2025 was $905000.0 at Northwest Biotherapeutics, up from $202000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.7 million in Q3 2021 to a low of $58000.0 in Q1 2022.
  • The 5-year median for Capital Expenditures is $413000.0 (2022), against an average of $743600.0.
  • The sharpest move saw Capital Expenditures crashed 89.74% in 2022, then soared 2198.28% in 2023.
  • Year by year, Capital Expenditures stood at $1.6 million in 2021, then surged by 39.09% to $2.2 million in 2022, then plummeted by 80.65% to $418000.0 in 2023, then plummeted by 81.34% to $78000.0 in 2024, then surged by 1060.26% to $905000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $905000.0, $202000.0, and $304000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.